4D Molecular Therapeutics, Inc. (FDMT) — Financial statements
Income statement, balance sheet, and cash flow for 4D Molecular Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 85↑230194.6% | 0.04↓99.8% | 21↑562.3% | 3↓82.7% | 18 | |
| Cost of Revenue | 8 | 0.00↓100.0% | 97↑21.0% | 80↑30.8% | 61 | |
| Gross Profit | 78↑209586.5% | 0.04↑100.0% | -76↑1.0% | -77↓78.0% | -43 | |
| Operating Expenses | ||||||
| R&D Expenses | 196↑38.5% | 141↑45.5% | 97↑21.0% | 80↑30.8% | 61 | |
| General & Administrative Expenses | 49↑5.3% | 47↑27.6% | 36↑10.9% | 33↑17.5% | 28 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 49↑5.3% | 47↑27.6% | 36↑10.9% | 33↑17.5% | 28 | |
| Other Expenses | -8 | 0.00↑100.0% | -97↓21.0% | -80↓30.8% | -61 | |
| Operating Expenses | 237↑26.2% | 188↑414.8% | 36↑10.9% | 33↑17.5% | 28 | |
| Total Costs & Expenses | 245↑30.3% | 188↑40.6% | 134↑18.1% | 113↑26.6% | 89 | |
| Operating Results | ||||||
| Operating Income | -160↑15.1% | -188↓66.4% | -113↓2.6% | -110↓54.3% | -71 | |
| Depreciation & Amortization | 8↑13.7% | 7↑59.5% | 4↑74.9% | 2↑57.8% | 2 | |
| EBITDA | -152↑16.1% | -181↓66.7% | -109↓1.0% | -108↓54.2% | -70 | |
| EBIT | -160↑15.1% | -188↓66.4% | -113↓2.6% | -110↓54.3% | -71 | |
| Interest & Other Income | ||||||
| Net Interest Income | 19↓28.0% | 27↑121.5% | 12↑374.6% | 3↑1778.1% | 0.14 | |
| Interest Income | 19↓28.0% | 27↑121.5% | 12↑374.6% | 3↑1778.1% | 0.14 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 19↓27.9% | 27↑124.2% | 12↑374.0% | 3↑15762.5% | 0.02 | |
| Income Before Tax | -140↑12.9% | -161↓59.5% | -101↑6.2% | -107↓50.7% | -71 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -140↑12.9% | -161↓59.5% | -101↑6.2% | -107↓50.7% | -71 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -140↑12.9% | -161↓59.5% | -101↑6.2% | -107↓50.7% | -71 | |
| Bottom-Line Net Income | -140↑12.9% | -161↓59.5% | -101↑6.2% | -107↓50.7% | -71 | |
| EPS (Basic) | -2.42↑18.8% | -2.98↓15.5% | -2.58↑17.3% | -3.12↓26.8% | -2.46 | |
| EPS (Diluted) | -2.42↑18.8% | -2.98↓15.5% | -2.58↑17.3% | -3.12↓26.8% | -2.46 | |
| Weighted Average Shares | 58↑7.4% | 54↑37.9% | 39↑21.0% | 32↑16.7% | 28 | |
| Weighted Average Diluted Shares | 58↑7.4% | 54↑37.9% | 39↑21.0% | 32↑16.7% | 28 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.